Centrient Pharmaceuticals Netherlands B.V.
Centrient Pharmaceuticals Netherlands B.V., a leading player in the pharmaceutical industry, is headquartered in the Netherlands and operates across various regions globally. Founded in 2017, the company has quickly established itself as a key provider of essential medicines, particularly in the areas of antibiotics and anti-infectives. Centrient is renowned for its innovative approach to manufacturing and supplying high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Their commitment to sustainability and efficiency sets them apart in a competitive market. With a strong focus on meeting the needs of healthcare providers and patients, Centrient has achieved significant milestones, including expanding its product portfolio and enhancing its market presence. As a trusted partner in the healthcare sector, Centrient Pharmaceuticals continues to drive advancements in pharmaceutical solutions, reinforcing its position as a vital contributor to global health.
DitchCarbon Score
How does Centrient Pharmaceuticals Netherlands B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Centrient Pharmaceuticals Netherlands B.V.'s score of 17 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Centrient Pharmaceuticals Netherlands B.V.'s reported carbon emissions
Centrient Pharmaceuticals Netherlands B.V. has reported its carbon emissions data for the years 2018 to 2021, focusing on Scope 1 and Scope 2 emissions. In 2021, the company emitted approximately 290,379,000 kg CO2e, comprising about 87,494,000 kg CO2e from Scope 1 and about 202,885,000 kg CO2e from Scope 2. This marked a reduction from 2020, where total emissions were about 271,611,000 kg CO2e. In 2020, the emissions were approximately 81,942,000 kg CO2e for Scope 1 and about 189,669,000 kg CO2e for Scope 2. The trend shows a decrease in emissions from 2018, which recorded about 364,138,000 kg CO2e in total (121,708,000 kg CO2e from Scope 1 and 242,430,000 kg CO2e from Scope 2). Despite these reductions, Centrient Pharmaceuticals has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to focus on improving its greenhouse gas (GHG) intensity, which was reported at approximately 18,750 kg CO2e per tonne of product in 2021. Centrient Pharmaceuticals is committed to addressing its carbon footprint, although further details on specific climate commitments or future reduction targets remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Scope 1 | 121,708,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 242,430,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Centrient Pharmaceuticals Netherlands B.V. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
